The Bio-inflammation Company

Transforming Human Health Through The Restoration Of Ammonia-Oxidizing Bacteria

Our Pruritus/Eczema (Itch) Clinical Research Study is Enrolling Now: LEARN MORE

 

An evolutionary approach to restoring health

AOBiome Therapeutics is a clinical-stage therapeutics company addressing a broad range of inflammatory conditions by harnessing a single strain of class defining
Ammonia Oxidizing Bacteria (AOB).

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

Learn More

AOBiome currently has multiple
Phase 2 clinical programs

AOBiome currently has Phase 2 clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea.

 

Learn More

Committed to transforming & improving human health

We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.

 

In the News
Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome’s B244 Ammonia Oxidizing Bacteria drug therapy
AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults
AOBiome Featured on NPR’s Marketplace